Download μορια- πιθανοι θεραπευτικοι στοχοι του hiv

ΜΟΡΙΑ- ΠΙΘΑΝΟΙ ΘΕΡΑΠΕΥΤΙΚΟΙ
ΣΤΟΧΟΙ ΤΟΥ HIV
Κωστούλα Ευγενία-Αγγελική
Εφραιμίδης Ιάσονας
S
Στόχοι για την αναστολή του κύκλου ζωής του ιού
με φαρμακολογικούς παράγοντες
Τρόπος Δράσης
Έγκριση FDA
Reverse Transcriptase Inhibitors (RTIs)
• Nucleoside/Nucleotide Analogues (NRTIs)
• Nonnucleoside Reverse Transcriptase Inhibitors
(NNRTIs)
1987
1996
Protease Inhibitors (PIs)
1995
Fixed-Dose Combination Antiretrovirals
Fusion Inhibitors
2003
Chemokine Coreceptor Antagonists
2007
Integrase Inhibitors
2007
Maturation Inhibitors
HIV-1 uses dynamic capsid pores to import nucleotide
and fuel encapsidated DNA synthesis.
S August, 2016 (Nature)
S Scientists from UCL and Cambridge
S Hexameric Hiv-1 CA in Complex With
Hexacarboxybenzene
Jacques DA, McEwan WA. Nature, 2016
Ibalizumab monoclonal antibody looks promising
for people with drug-resistant HIV
S November, 2016 (IDWeek 2016, New
Orleans)
S US FDA (to be approved in 2016)
S First biologic drug for HIV
Lalezari J et al. Primary efficacy endpoint and safety results of ibalizumab (IBA) in a phase 3 study of heavily
treatment-experienced patients with multi-drug resistant (MDR) HIV-1 infection. IDWeek, New Orleans, abstract LB-6,
2016.
Activation of HIV Transcription with Short-Course
Vorinostat in HIV-Infected Patients on Suppressive
Antiretroviral Therapy
S HAART (Highly Active Antiretroviral
Therapy)
S November, 2014- October, 2016
S 50 patients, 5 UK Universities
Julian H. Elliott , Fiona Wightman. November, 2014.
Sarah Fidler, Imperial College, London. October, 2016.
Ευχαριστούμε για την προσοχή σας